Halia Therapeutics, Inc.’s Post

Halia’s CEO David Bearss Ph.D. will be speaking at the 5th Inflammasome Therapeutics Summit in Boston about Halia’s efforts to combat chronic inflammation by inhibiting the inflammasome NLRP3. Dave will discuss the early clinical evaluation of Halia’s NLRP3 inhibitor, HT-6184, and its activity as a selective, orally bioavailable, allosteric inhibitor of Nek7/NLRP3. For more information about the Summit, go to: https://lnkd.in/et3h9AQd #inflammasome #chronicinflammation #inflammasometherapeuticssummit #NLRP3 #therapeutics

Molecules of the Month - August 23 | https://lnkd.in/djuSW2aA This month features many of the big reveals from the ACS fall 2023 first disclosures including Nurix Therapeutics' BTK degrader and RAPT’s second generation CCR4 antagonist for atopic dermatitis. Several of the molecules making the August list are in Ph. III clinical trials such as Vertex Pharmaceuticals' sodium channel inhibitor for acute pain and Denali Therapeutics' CNS-penetrant eIF2B activator for ALS. Links to recent articles are on the website page - follow our page to make sure you don't miss any of the upcoming case studies! #chemistry #drugdiscovery #pharmaceutials #medicine #drughunter

JJP Biologics's JJP-1212 is the first programme worldwide exploring the CD89-IgA axis in clinical stage. Results of ongoing cohorts are promising. Stay tuned! #jjpbiologics #jjp1212 #smartstrategy

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Anticipating Remarkable Growth by 2032, Insights by DelveInsight | Eidos Therapeutics (Acoramidis/AG 10), NeuraImmune Therapeutics (NI006) #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

Today! Last chance to join this webinar. Dr Torsten Wuestefeld and Dr Si Hui Tan from Lerna Biopharma (Formerly known as Cargene Therapeutics) discuss how they are using #siRNA as a modality to accelerate therapeutic development for liver #diseases with high unmet needs in this upcoming webinar. Register here: https://hubs.li/Q027ppn40 #siRNA #liverdisease SelectScience®

Although JJP-1212 is developed by JJP Biologics the scientific background around the CD89-IgA axis remains an highly unexplored field.

Back-to-back development candidates progressing into the clinic is no mean feat! Following on the footsteps of VYN201 which progressed into Phase 2b last month; this week we are delighted to share that dosing of the first participants in the Phase 1a trial of VYN202 has taken place. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immuno-inflammatory diseases. VYN202 was discovered by the team at Tay Therapeutics before being licensed to VYNE Therapeutics who are leading clinical development. Top-line data is expected in the second half of 2024. https://lnkd.in/ePG4eb7V https://lnkd.in/eGtRw7Ty

Cell therapy history was made, FDA approves first two Eylea biosimilars, Gilead's $4.3B liver disease bet yields positive ph3 data, and a trilogy of lung disease positive trial data. All this and more in today's TLDR Biotech newsletter - it's the latest issue on the homepage https://tldrbio.tech/. If you don't want to miss any of these daily updates, you can sign-up to the newsletter using the above link. #biotechnews #biotech #pharmnews #pharma #tldrbiotech

Aileron Therapeutics Reveals Cohort 1 Data from the P-Ib Clinical Evaluation of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF) #ailerontherapeutics #lti03 #idiopathicpulmonaryfibrosis #clinicaltrial #phase1 #safety #efficacy #tolerability #inflammation #fibrosis #ipf

Alentis Therapeutics is moving forward with new clinical advancements!   Our portfolio company today announced the first patient dosed in a Phase 2 clinical trial of lixudebart (formerly named ALE.F02), a Claudin-1 targeting investigational antibody for the treatment of organ fibrosis.   The study evaluates the drug’s safety, tolerability, pharmacokinetics, and how well it protects against the loss of kidney function in patients with Antineutrophil Cytoplasmic Antibody (ANCA) associated vasculitis with Rapidly Progressive Glomerulonephritis (RPGN).   It is the second clinical trial investigating lixudebart in patients after the initiation of a clinical study in advanced liver fibrosis patients earlier this year.   Read more 👉 https://lnkd.in/eiHUTCnE   #fasterforthepatient #clinicalstudy #fibrosis #biopharma